Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
28.18
+0.36 (1.29%)
Mar 9, 2026, 1:18 PM EDT - Market open

Edgewise Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Selling, General & Admin
40.0231.8723.4517.6311.03
Upgrade
Research & Development
151.39126.9790.9154.0332.19
Upgrade
Operating Expenses
191.41158.83114.3671.6643.22
Upgrade
Operating Income
-191.41-158.83-114.36-71.66-43.22
Upgrade
Interest & Investment Income
23.6125.0214.194.020.4
Upgrade
Pretax Income
-167.8-133.81-100.16-67.64-42.81
Upgrade
Net Income
-167.8-133.81-100.16-67.64-42.81
Upgrade
Net Income to Common
-167.8-133.81-100.16-67.64-42.81
Upgrade
Shares Outstanding (Basic)
10392645438
Upgrade
Shares Outstanding (Diluted)
10392645438
Upgrade
Shares Change (YoY)
11.38%45.02%18.90%42.82%4977.96%
Upgrade
EPS (Basic)
-1.63-1.45-1.57-1.26-1.14
Upgrade
EPS (Diluted)
-1.63-1.45-1.57-1.26-1.14
Upgrade
Free Cash Flow
-144.07-110.34-97.69-58.18-34.18
Upgrade
Free Cash Flow Per Share
-1.40-1.19-1.53-1.09-0.91
Upgrade
EBITDA
-189.32-156.76-112.81-71.29-42.94
Upgrade
D&A For EBITDA
2.082.071.550.370.27
Upgrade
EBIT
-191.41-158.83-114.36-71.66-43.22
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.